CA2707733C - Advantageous salts of mu-opiate receptor peptides - Google Patents

Advantageous salts of mu-opiate receptor peptides Download PDF

Info

Publication number
CA2707733C
CA2707733C CA2707733A CA2707733A CA2707733C CA 2707733 C CA2707733 C CA 2707733C CA 2707733 A CA2707733 A CA 2707733A CA 2707733 A CA2707733 A CA 2707733A CA 2707733 C CA2707733 C CA 2707733C
Authority
CA
Canada
Prior art keywords
salt
salts
sample
scaled
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2707733A
Other languages
English (en)
French (fr)
Other versions
CA2707733A1 (en
Inventor
Theodore E. Maione
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogel Pharma LLC
Original Assignee
Cytogel Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogel Pharma LLC filed Critical Cytogel Pharma LLC
Priority to CA2984218A priority Critical patent/CA2984218C/en
Publication of CA2707733A1 publication Critical patent/CA2707733A1/en
Application granted granted Critical
Publication of CA2707733C publication Critical patent/CA2707733C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2707733A 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides Expired - Fee Related CA2707733C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2984218A CA2984218C (en) 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US761707P 2007-12-13 2007-12-13
US61/007,617 2007-12-13
PCT/US2008/086838 WO2009076672A1 (en) 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2984218A Division CA2984218C (en) 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides

Publications (2)

Publication Number Publication Date
CA2707733A1 CA2707733A1 (en) 2009-06-18
CA2707733C true CA2707733C (en) 2018-01-02

Family

ID=40755912

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2707733A Expired - Fee Related CA2707733C (en) 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides
CA2984218A Expired - Fee Related CA2984218C (en) 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2984218A Expired - Fee Related CA2984218C (en) 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides

Country Status (7)

Country Link
US (6) US20110190214A1 (OSRAM)
EP (2) EP2229400B1 (OSRAM)
JP (1) JP5647002B2 (OSRAM)
AU (1) AU2008334941B2 (OSRAM)
CA (2) CA2707733C (OSRAM)
ES (1) ES2550604T3 (OSRAM)
WO (1) WO2009076672A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065648A1 (en) * 2009-09-15 2011-03-17 Maione Theodore E Advantageous mu-opiate receptor peptide compounds
EP2574172A4 (en) 2010-05-21 2013-10-30 Cytogel Pharma Llc MATERIALS AND METHOD FOR TREATING INFLAMMATION
US20150126455A1 (en) * 2012-05-18 2015-05-07 Cytogel Pharma, Llc. Novel Therapeutic Uses of Mu-Opiate Receptor Peptides
WO2018231838A1 (en) * 2017-06-12 2018-12-20 Board Of Regents Of The University Of Nebraska Hydrochloride salts of c5a receptor agonist peptides
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
JP2021503481A (ja) * 2017-11-17 2021-02-12 サイトジェル ファーマ リミテッド ライアビリティ カンパニー μオピオイド受容体のポリマーアゴニスト

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235496B1 (en) * 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
JPH10330398A (ja) * 1997-05-28 1998-12-15 Asahi Glass Co Ltd 新規環状ペプチド
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
AU2002324133A1 (en) 2001-09-03 2003-03-18 The University Of Bristol Inflammation modulatory compound comprising an endomorphin
WO2003066593A2 (en) * 2001-11-29 2003-08-14 Schering Corporation Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl )-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-methyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections

Also Published As

Publication number Publication date
EP2826786B1 (en) 2015-09-23
US20150152137A1 (en) 2015-06-04
HK1206363A1 (en) 2016-01-08
US20200339628A1 (en) 2020-10-29
US20140142050A1 (en) 2014-05-22
JP5647002B2 (ja) 2014-12-24
AU2008334941B2 (en) 2013-02-14
CA2984218C (en) 2019-12-31
EP2229400A4 (en) 2012-01-04
US20110190214A1 (en) 2011-08-04
WO2009076672A1 (en) 2009-06-18
CA2984218A1 (en) 2009-06-18
AU2008334941A1 (en) 2009-06-18
EP2229400A1 (en) 2010-09-22
US20220324908A1 (en) 2022-10-13
US20180291060A1 (en) 2018-10-11
EP2826786A1 (en) 2015-01-21
CA2707733A1 (en) 2009-06-18
EP2229400B1 (en) 2014-11-19
US8940704B2 (en) 2015-01-27
ES2550604T3 (es) 2015-11-11
JP2011508727A (ja) 2011-03-17

Similar Documents

Publication Publication Date Title
US20220324908A1 (en) Advantageous salts of mu-opiate receptor peptides
US6242460B1 (en) Zolpidem salt forms
JP2021530456A (ja) ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態
CA2743172A1 (en) Crystalline form of linaclotide
WO2024006568A1 (en) Salts of l-ergothioneine and crystalline forms thereof
US11136332B2 (en) Morphic forms of marizomib and uses thereof
US20130143846A1 (en) Polymorphic form of a calcimimetic compound
HK1206363B (en) Advantageous salts of mu-opiate receptor peptides
EP1163241A1 (en) Zolpidem salts
NO160081B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive tripeptider.
US20250388550A1 (en) Salts of an antioxidant and crystalline forms thereof
US12448347B2 (en) Polymorphic forms of (R)-oxybutynin hydrochloride
WO2025231285A1 (en) Peptide analogs and methods of using the same
US20130131023A1 (en) New polymorphic form of a calcimimetic compound
EP3941588A1 (en) Co-crystal forms of selinexor
WO2019209908A1 (en) Crystalline forms of dasatinib

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131121

MKLA Lapsed

Effective date: 20201215